Severe, sometimes fatal, hemorrhagic events may occur. Avoid use in recent hemoptysis (>2.5 mL blood). Serious, sometimes fatal, arterial thromboembolic events reported (increased risk in patients ≥65 years of age and in patients receiving bevacizumab for metastatic colorectal cancer). Severe neutropenia, febrile neutropenia, and serious infection (including pneumonia, catheter infections, and wound infections), sometimes fatal, reported. Gastrointestinal perforation, fistula (including gastrointestinal, enterocutaneous, esophageal, duodenal, and rectal fistulas), and intra-abdominal abscess reported in colorectal cancer or non-small cell lung cancer. Non-gastrointestinal fistula formation (tracheo-esophageal, bronchopleural, biliary, vagina, and bladder), sometimes fatal, reported. May cause and/or worsen hypertension significantly (use caution in pre-existing hypertension). Cases of reversible posterior leukoencephalopathy syndrome reported. Infusion reactions (hypertension, hypertensive crisis, wheezing, hypersensitivity, chest pain, headache, diaphoresis) may occur with the first infusion (uncommon). Proteinuria and/or nephrotic syndrome associated with use (increased risk of proteinuria in patients ≥65 years of age receiving bevacizumab in combination with paclitaxel-carboplatin). Wound dehiscence/wound healing complications reported. Caution in cardiovascular disease. Avoid use in CNS metastases. May potentiate cardiotoxic effects of anthracyclines. When used in combination with myelosuppressive chemotherapy, increased rates of severe or febrile neutropenia and neutropenic infection reported. Potential for immunogenicity.